Fortress Biotech (NASDAQ:FBIO) Stock: Insider David Jin Acquires 25,000 Shares

Fortress Biotech, Inc. (NASDAQ:FBIO – Get Free Report) CFO David Jin bought 25,000 shares of the business’s stock in a transaction on Wednesday, November 18th. The stock was acquired at an average cost of $1.91 per share, for a total transaction of $47,750.00. Following the completion of the transaction, the chief financial officer owned 1,692,761 shares in the company, valued at $3,233,173.51. This represents a 1.50% increase in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink.

David Jin also recently made the following trade(s):

  • On Thursday, November 19th, David Jin bought 7,605 shares of Fortress Biotech stock. The shares were acquired at an average price of $1.87 per share, with a total value of $14,221.35.
  • On Tuesday, November 17th, David Jin purchased 15,000 shares of Fortress Biotech stock. The shares were bought at an average cost of $1.72 per share, with a total value of $25,800.00.

Fortress Biotech Stock Up 7.3%

Shares of NASDAQ:FBIO opened at $1.90 on Friday. The company has a current ratio of 2.93, a quick ratio of 3.83 and a debt-to-equity ratio of 0.10. The company has a fifty day simple moving average of $2.06 and a 200 day simple moving average of $2.69. The firm has a market cap of $64.11 million, a PE ratio of 0.83 and a beta of 1.27. Fortress Biotech, Inc. has a 12-month low of $1.64 and a 12-month high of $4.53.

Fortress Biotech (NASDAQ:FBIO – Get Free Report) last posted its quarterly earnings data on Friday, November 13th. The biopharmaceutical company reported ($0.23) EPS for the quarter, beating analysts’ consensus estimates of ($0.27) by $0.04. The firm had revenue of $19.16 million for the quarter, compared to the consensus estimate of $21.57 million. Fortress Biotech had a net margin of 143.04% and a return on equity of 61.84%. On average, equities research analysts anticipate that Fortress Biotech, Inc. will post 2.66 EPS for the current fiscal year.

Latest Fortress Biotech News

Investors following FBIO have been watching these news items:

  • Positive Sentiment: CEO Lindsay Rosenwald and CFO David Jin bought a combined 184,328 shares from November 17–19, investing approximately $340,000. These purchases increased their existing holdings and may signal confidence, although insider buying does not guarantee improving business fundamentals. Insider buying report
  • Neutral Sentiment: Zacks Research initiated coverage with a “hold” rating, offering no clear directional signal for the shares. Zacks rating information
  • Negative Sentiment: HC Wainwright forecasts EPS of $2.37 for FY2027, below its $2.66 estimate for FY2026. The estimates are not company guidance, but the year-over-year decline could temper optimism. Earnings estimate report

Hedge Funds Weigh In On Fortress Biotech

Hedge funds have recently added to or reduced their stakes in the business. Marshall Wace LLP bought a new stake in Fortress Biotech during the third quarter valued at $462,000. Squarepoint Ops LLC bought a new position in shares of Fortress Biotech in the 2nd quarter worth about $47,000. Finally, Renaissance Technologies LLC lifted its position in shares of Fortress Biotech by 22.8% in the 1st quarter. Renaissance Technologies LLC now owns 99,590 shares of the biopharmaceutical company’s stock worth $278,000 after buying an additional 18,490 shares during the last quarter. Institutional investors and hedge funds own 96.51% of the company’s stock.

Analysts Set New Price Targets

Several equities analysts have recently commented on the stock. Weiss Ratings cut shares of Fortress Biotech from a “hold (c-)” rating to a “sell (d+)” rating in a research report on Friday, October 23rd. Wall Street Zen downgraded Fortress Biotech from a “strong-buy” rating to a “hold” rating in a research note on Saturday, August 15th. Finally, Zacks Research assumed coverage on Fortress Biotech in a report on Wednesday. They issued a “hold” rating for the company. Two investment analysts have rated the stock with a Buy rating, one has given a Hold rating and one has given a Sell rating to the stock. According to MarketBeat, the stock currently has a consensus rating of “Hold” and a consensus price target of $17.00.

Check Out Our Latest Analysis on Fortress Biotech

About Fortress Biotech

(Get Free Report)

Fortress Biotech, Inc. is a biopharmaceutical company that develops and commercializes prescription medicines through a network of subsidiaries and affiliated companies. Its approach includes advancing drug candidates, acquiring or licensing development and commercialization rights, and building companies around selected products and programs. The company’s activities span areas including oncology, dermatology, rare diseases and immunology. Its portfolio has included marketed dermatology medicines such as Qbrexza, Amzeeq and Zilxi, as well as investigational therapies at various stages of development.

Further Reading

Receive News & Ratings for Fortress Biotech Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Fortress Biotech and related companies with MarketBeat.com's FREE daily email newsletter.